Skip to main content
Erschienen in: Clinical Rheumatology 8/2020

04.03.2020 | Original Article

Macrophage activation syndrome associated with adult-onset Still’s disease: a multicenter retrospective analysis

verfasst von: Ran Wang, Ting Li, Shuang Ye, Wenfeng Tan, Cheng Zhao, Yisha Li, Chun de Bao, Qiong Fu

Erschienen in: Clinical Rheumatology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To explore the clinical features, treatments, and prognostic factors of adult-onset Still’s disease (AOSD)-associated macrophage activation syndrome (MAS), we conducted a multicenter retrospective clinical study of AOSD-associated MAS patients.

Methods

AOSD patients were collected from six tertiary hospitals in China. Medical charts were reviewed and clinical information was recorded and analyzed.

Results

There were 447 AOSD patients enrolled into this retrospective clinical study. Among them, 55 were diagnosed with MAS. Liver dysfunction was the most reliable predictive factor for the screening of MAS in AOSD patients (OR = 75.744, 95%CI = 23.015–249.284, p < 0.0001). In multivariate analysis, clinical features including platelets < 100 × 109/L (OR = 9.546, p = 0.005), aspartate transaminase (AST) > 120 U/L (OR = 25.853, p < 0.0001), triglycerides > 3 mmol/L (OR = 12.9833, p = 0.011)), ferritin > 1500 ng/mL (OR = 5.513, p = 0.050), as well as hemophagocytosis in bone puncture (OR = 18.132, p = 0.001) were highly associated with the occurrence of MAS. The mortality rate of total AOSD patients was 4.47%, MAS was the main cause of death in AOSD patients (OR = 11.705, 95%CI = 4.783–28.647, p < 0.0001). PLT ≤ 100 × 109/L (p = 0.0001), fibrinogen < 1.5 g/L (p = 0.0286), splenomegaly (p = 0.0002), and liver dysfunction (p = 0.0008) highly suggested poor prognosis.

Conclusion

MAS occurrence is the major cause of death in AOSD patients. Notable liver dysfunction, as well as splenomegaly, low number of platelets or neutrophils, high levels of serum ferritin, and reduced level of fibrinogen are risk factors for poor outcome.
Key Points
This is a multicenter retrospective study of AOSD-associated MAS with large number of cases.
Literatur
3.
Zurück zum Zitat Larson EB (1985) Adult Still’s disease--recognition of a clinical syndrome and recent experience. West J Med 142(5):665–671PubMedPubMedCentral Larson EB (1985) Adult Still’s disease--recognition of a clinical syndrome and recent experience. West J Med 142(5):665–671PubMedPubMedCentral
11.
Zurück zum Zitat Henter JI, Horne A, Arico M (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131CrossRef Henter JI, Horne A, Arico M (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131CrossRef
14.
Zurück zum Zitat Ravelli A, Minoia F, Davi S et al (2016) 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 68(3):566–576. https://doi.org/10.1002/art.39332CrossRefPubMed Ravelli A, Minoia F, Davi S et al (2016) 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 68(3):566–576. https://​doi.​org/​10.​1002/​art.​39332CrossRefPubMed
23.
24.
Zurück zum Zitat Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, Koroglu TF, Dursun O, Erkek N, Gedik H, Citak A, Kesici S, Karabocuoglu M, Carcillo JA, Turkish Secondary HLH/MAS Critical Care Study Group (2012) Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care 16(2):R52. https://doi.org/10.1186/cc11256CrossRefPubMedPubMedCentral Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, Koroglu TF, Dursun O, Erkek N, Gedik H, Citak A, Kesici S, Karabocuoglu M, Carcillo JA, Turkish Secondary HLH/MAS Critical Care Study Group (2012) Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care 16(2):R52. https://​doi.​org/​10.​1186/​cc11256CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Sung L, King SM, Carcao M et al (2002) Adverse outcomes in primary hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 24(7):550–554CrossRef Sung L, King SM, Carcao M et al (2002) Adverse outcomes in primary hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 24(7):550–554CrossRef
30.
Zurück zum Zitat Jin J (2016) A continuous infusion of etoposide and doxorubicin for refractory MAS management. Neth J Med 74(7):324–325PubMed Jin J (2016) A continuous infusion of etoposide and doxorubicin for refractory MAS management. Neth J Med 74(7):324–325PubMed
Metadaten
Titel
Macrophage activation syndrome associated with adult-onset Still’s disease: a multicenter retrospective analysis
verfasst von
Ran Wang
Ting Li
Shuang Ye
Wenfeng Tan
Cheng Zhao
Yisha Li
Chun de Bao
Qiong Fu
Publikationsdatum
04.03.2020
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 8/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-04949-0

Weitere Artikel der Ausgabe 8/2020

Clinical Rheumatology 8/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.